Rafferty Asset Management
IONS icon

Rafferty Asset Management’s Ionis Pharmaceuticals IONS Stock Holding History

Rafferty Asset Management’s Portfolio IONS Stock Details IONS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$4.53M Sell
60,308
-13,675
-18% -$1.08M 0.02% 422
2025
Q4 		$5.85M Sell
73,983
-51,790
-41% -$3.9M 0.02% 387
2025
Q3 		$8.23M Sell
125,773
-18,997
-13% -$927K 0.03% 319
2025
Q2 		$5.72M Sell
144,770
-31,478
-18% -$1.03M 0.02% 369
2025
Q1 		$5.32M Sell
176,248
-61,089
-26% -$2M 0.02% 360
2024
Q4 		$8.3M Buy
237,337
+38,578
+19% +$1.44M 0.03% 319
2024
Q3 		$7.96M Buy
198,759
+29,903
+18% +$1.39M 0.03% 319
2024
Q2 		$8.05M Sell
168,856
-39,613
-19% -$1.62M 0.03% 319
2024
Q1 		$9.04M Buy
208,469
+24,073
+13% +$1.15M 0.03% 297
2023
Q4 		$9.33M Sell
184,396
-31,575
-15% -$1.51M 0.04% 299
2023
Q3 		$9.8M Buy
215,971
+11,583
+6% +$478K 0.06% 230
2023
Q2 		$8.39M Buy
204,388
+501
+0.2% +$19.3K 0.05% 253
2023
Q1 		$7.29M Sell
203,887
-15,092
-7% -$567K 0.05% 277
2022
Q4 		$8.27M Buy
218,979
+67,005
+44% +$2.82M 0.07% 249
2022
Q3 		$6.72M Buy
151,974
+32,691
+27% +$1.38M 0.07% 235
2022
Q2 		$4.42M Sell
119,283
-59,511
-33% -$2.24M 0.04% 302
2022
Q1 		$6.62M Sell
178,794
-10,845
-6% -$355K 0.04% 294
2021
Q4 		$5.77M Buy
189,639
+92,902
+96% +$2.92M 0.03% 323
2021
Q3 		$3.25M Buy
96,737
+27,965
+41% +$1.05M 0.02% 432
2021
Q2 		$2.74M Buy
68,772
+5,888
+9% +$231K 0.02% 535
2021
Q1 		$2.83M Buy
62,884
+42,536
+209% +$2.37M 0.02% 528
2020
Q4 		$1.15M Sell
20,348
-17,831
-47% -$889K 0.01% 472
2020
Q3 		$1.81M Buy
38,179
+21,695
+132% +$1.21M 0.02% 448
2020
Q2 		$972K Buy
16,484
+8,990
+120% +$500K 0.01% 556
2020
Q1 		$354K Sell
7,494
-54,943
-88% -$3.06M 0.01% 396
2019
Q4 		$3.77M Sell
62,437
-35,726
-36% -$2.13M 0.06% 181
2019
Q3 		$5.88M Buy
98,163
+18,299
+23% +$1.19M 0.09% 133
2019
Q2 		$5.13M Buy
79,864
+9,477
+13% +$670K 0.09% 161
2019
Q1 		$5.71M Buy
+70,387
New +$4.54M 0.09% 116

Other funds holding IONS

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Rafferty Asset Management's IONS Position: Q1 2026 in Review

Rafferty Asset Management reduced its Ionis Pharmaceuticals (IONS) stake by 18% in Q1 2026, selling an estimated $1.08M and leaving 60,308 shares worth $4.53M. The position accounts for 0.02% of the portfolio, ranked #422.

Rafferty Asset Management first reported a position in IONS in Q1 2019 and has held it in 29 quarters since. The position peaked at $9.8M in Q3 2023. 493 funds tracked by Wall St. Rank hold IONS as of Q1 2026.

  • Rafferty Asset Management held 60,308 shares of Ionis Pharmaceuticals worth $4.53M as of Q1 2026.
  • Rafferty Asset Management sold 13,675 Ionis Pharmaceuticals shares in Q1 2026, an estimated $1.08M.
  • Ionis Pharmaceuticals made up 0.02% of Rafferty Asset Management's portfolio in Q1 2026, its #422 holding.
  • Rafferty Asset Management first reported a position in Ionis Pharmaceuticals in Q1 2019 and has held it in 29 quarters since.
  • Rafferty Asset Management's Ionis Pharmaceuticals position peaked at $9.8M in Q3 2023.
  • 493 funds tracked by Wall St. Rank held Ionis Pharmaceuticals as of Q1 2026.

Based on Rafferty Asset Management's 13F filing for Q1 2026, filed 15 May 2026.